Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Cash from Operations (2020 - 2025)

Foghorn Therapeutics has reported Cash from Operations over the past 6 years, most recently at 22271000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 22271000.0 for Q4 2025, up 9.17% from a year ago — trailing twelve months through Dec 2025 was 86099000.0 (up 14.25% YoY), and the annual figure for FY2025 was 86099000.0, up 14.25%.
  • Cash from Operations for Q4 2025 was 22271000.0 at Foghorn Therapeutics, down from 18860000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for FHTX hit a ceiling of 271534000.0 in Q1 2022 and a floor of 32175000.0 in Q2 2023.
  • Median Cash from Operations over the past 5 years was 23557500.0 (2021), compared with a mean of 8062450.0.
  • Biggest five-year swings in Cash from Operations: plummeted 852.09% in 2021 and later surged 1273.09% in 2022.
  • Foghorn Therapeutics' Cash from Operations stood at 11882000.0 in 2021, then crashed by 343.43% to 28924000.0 in 2022, then rose by 4.78% to 27541000.0 in 2023, then grew by 10.97% to 24519000.0 in 2024, then increased by 9.17% to 22271000.0 in 2025.
  • The last three reported values for Cash from Operations were 22271000.0 (Q4 2025), 18860000.0 (Q3 2025), and 21000000.0 (Q2 2025) per Business Quant data.